Time dependency of prognostic factors in patients with stage II osteosarcomas

Clinical Orthopaedics and Related Research

Volumn 463, Issue , 2007, Pages 157-165

  Kim, Min Suk ^a   Cho, Wan Hyeong ^a   Song, Won Seok ^a   Lee, Soo Yong ^a   Jeon, Dae Geun ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; MEDRONATE TECHNETIUM TC 99M; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARTILAGE CELL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TIME; BONE TUMOR; DISEASE FREE SURVIVAL; FEMUR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRESCHOOL CHILD; TIBIA; TUMOR RECURRENCE;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FEMUR; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TIBIA; TIME FACTORS;

EID: 35348899137     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/BLO.0b013e318142b27d     Document Type: Article

References (26)

1. Bacci G, Longhi A, Cesari M, Versari M, Bertoni F. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer. 2006;106:2701-2706.
2. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, Picci P. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer. 2005;41:2079-2085.
3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in highgrade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
4. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848-858.
5. Bolard P, Quantin C, Esteve J, Faivre J, Abrahamowicz M. Modelling time-dependent hazard ratios in relative survival: application to colon cancer. J Clin Epidemiol. 2001;54:986-996.
6. Coradini D, Daidone MG, Boracchi P, Biganzoli E, Oriana S, Bresciani G, Pellizzaro C, Tomasic G, Di Fronzo G, Marubini E. Timedependent relevance of steroid receptors in breast cancer. J Clin Oncol. 2000;18:2702-2709.
7. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
8. Engellau J, Anderson H, Rydholm A, Bauer HC, Hall KS, Gustafson P, Akerman M, Meis-Kindblom J, Alvegard TA, Nilbert M; Scandinavian Sarcoma Group. Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group study of 338 malignant fibrous histiocytomas. Cancer. 2004;100:2233-2239.
9. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-120.
10. Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for nonmetastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145-1150.
11. Gebauer G, Fehm T, Lang N, Jager W. Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery. Breast Cancer Res Treat. 2002;75:167-173.
12. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma: the Memorial Hospital experience. Cancer. 1992;69:698-708.
13. Gobel V, Jurgens H, Etspuler G, Kemperdick H, Jungblut RM, Stienen U, Gobel U. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113:187-191.
14. th ed. New York, NY: Springer; 2002.
15. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707-1723.
16. Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H, Wallace S, Murray J, Robertson R. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
17. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286-291.
18. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
19. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, Figueiredo MT, Marques E, De Bellis N, Consentino E. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer. 1991;68:733-737.
20. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S. Primary osteogenic sarcoma: eightyear experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(suppl):55-67.
21. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg Am. 2002;84:49-57.
22. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Wist E, Valvere V, Takayama S, Reed JC, Saksela E. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res. 2002;8:811-816.
23. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol. 2002;20:4344-4352.
24. Taylor WF, Ivins JC, Unni KK, Beabout JW, Golenzer HJ, Black LE. Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst. 1989;81:21-30.
25. Warwick J, Tabar L, Vitak B, Duffy SW. Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study. Cancer. 2004;100:1331-1336.
26. Witzig TE, Ingle JN, Schaid DJ, Wold LE, Barlow JF, Gonchoroff NJ, Gerstner JB, Krook JE, Grant CS, Katzmann JA. DNA ploidy and percent S-phase as prognostic factors in node-positive breast cancer: results from patients enrolled in two prospective randomized trials. J Clin Oncol. 1993;11:351-359.